Heublein et al. also performed immunohistochemistry to evaluate the expression of THRβ using anti-THRβ polyclonal antibodies (Table 2) in a patient cohort with BRCA1-associated (n = 38, 31%) and sporadic BC (n = 86, 69%). This evidence concerns the gene BRCA1 and breast cancer.